Bullfrog AI Holdings shares surge 54.57% intraday after signing commercial deal with top-5 global pharmaceutical company to identify MDD drug targets using bfLEAP platform.

Bullfrog AI Holdings surged 54.57% intraday, driven by the company’s announcement of a commercial agreement with one of the top five global pharmaceutical firms. The deal utilizes Bullfrog’s proprietary bfLEAP platform to identify and prioritize novel drug targets for major depressive disorder (MDD), accelerating the client’s drug discovery and clinical development. The agreement grants the client exclusive rights to candidate targets and secures access to the MDD market, which exceeded $8 billion in 2025 and is projected to surpass $11 billion by 2032.